Natus Medical Incorporated

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating Natus (NASDAQ:NTUS) for possible breaches of fiduciary duty and other violations of law in its transaction with ArchiMed.

Ademi LLP alleges Natus’s financial outlook and prospects are excellent and yet Natus shareholders will receive only $33.50 per share. The transaction agreement unreasonably limits competing bids for Natus by prohibiting solicitation of further bids, and imposing a significant penalty if Natus accepts a superior bid. Natus insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Natus’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Natus.